{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:02:05Z","timestamp":1792443725420,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["No. 2019A-3"],"award-info":[{"award-number":["No. 2019A-3"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["Health"],"award-info":[{"award-number":["Health"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["Labour Sciences Research Grants for studies on intractable diseases (No.20FC1037)"],"award-info":[{"award-number":["Labour Sciences Research Grants for studies on intractable diseases (No.20FC1037)"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00535-022-01856-w","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T18:02:59Z","timestamp":1644861779000},"page":"344-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7173-0420","authenticated-orcid":false,"given":"Hirotaka","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ebana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hosoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"1856_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/00365529950172835","volume":"34","author":"AG Roseth","year":"1999","unstructured":"Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50\u20134.","journal-title":"Scand J Gastroenterol"},{"key":"1856_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/MPG.0000000000002092","volume":"67","author":"S Oliva","year":"2018","unstructured":"Oliva S, Thomson M, de Ridder L, et al. Endoscopy in pediatric inflammatory bowel disease: a position paper on behalf of the porto ibd group of the european society for pediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2018;67:414\u201330.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1856_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.dld.2005.07.012","volume":"37","author":"P Mamula","year":"2005","unstructured":"Mamula P, Markowitz JE, Neiswender K, et al. Success rate and duration of paediatric outpatient colonoscopy. Dig Liver Dis. 2005;37:877\u201381.","journal-title":"Dig Liver Dis"},{"key":"1856_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1053\/gast.2002.34755","volume":"123","author":"JA Tibble","year":"2002","unstructured":"Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450\u201360.","journal-title":"Gastroenterology"},{"key":"1856_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10620-014-3383-0","volume":"60","author":"E Burri","year":"2015","unstructured":"Burri E, Beglinger C, von Felten S, et al. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci. 2015;60:485\u201391.","journal-title":"Dig Dis Sci"},{"key":"1856_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","volume":"19","author":"AM Schoepfer","year":"2013","unstructured":"Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332\u201341.","journal-title":"Inflamm Bowel Dis"},{"key":"1856_CR7","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D'Haens","year":"2012","unstructured":"D\u2019Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218\u201324.","journal-title":"Inflamm Bowel Dis"},{"key":"1856_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ibd.20312","volume":"14","author":"T Sipponen","year":"2008","unstructured":"Sipponen T, Savilahti E, Kolho KL, et al. Crohn\u2019s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn\u2019s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40\u20136.","journal-title":"Inflamm Bowel Dis"},{"key":"1856_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3109\/00365521.2014.987809","volume":"50","author":"T Sipponen","year":"2015","unstructured":"Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74\u201380.","journal-title":"Scand J Gastroenterol"},{"key":"1856_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/01.MIB.0000438428.30800.a6","volume":"20","author":"E Mooiweer","year":"2014","unstructured":"Mooiweer E, Fidder HH, Siersema PD, et al. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2014;20:307\u201314.","journal-title":"Inflamm Bowel Dis"},{"key":"1856_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/ajg.2015.66","volume":"110","author":"S Takashima","year":"2015","unstructured":"Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110:873\u201380.","journal-title":"Am J Gastroenterol"},{"key":"1856_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/ajg.2013.131","volume":"109","author":"P Henderson","year":"2014","unstructured":"Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637\u201345.","journal-title":"Am J Gastroenterol"},{"key":"1856_CR13","doi-asserted-by":"publisher","first-page":"1450970","DOI":"10.1155\/2017\/1450970","volume":"2017","author":"S Kittanakom","year":"2017","unstructured":"Kittanakom S, Shajib MS, Garvie K, et al. Comparison of fecal calprotectin methods for predicting relapse of pediatric inflammatory bowel disease. Can J Gastroenterol Hepatol. 2017;2017:1450970.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1856_CR14","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2016-1012","author":"M Oyaert","year":"2017","unstructured":"Oyaert M, Boel A, Jacobs J, et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med (CCLM). 2017. https:\/\/doi.org\/10.1515\/cclm-2016-1012.","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"1856_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","volume":"58","author":"A Levine","year":"2014","unstructured":"Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795\u2013806.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1856_CR16","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625\u20139.","journal-title":"N Engl J Med"},{"key":"1856_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/ecco-jcc\/jjv111","volume":"9","author":"T Lobaton","year":"2015","unstructured":"Lobaton T, Bessissow T, De Hertogh G, et al. The modified mayo endoscopic score (MMES): a new index for the assessment of extension and severity of endoscopic activity in ulcerative colitis patients. J Crohns Colitis. 2015;9:846\u201352.","journal-title":"J Crohns Colitis"},{"key":"1856_CR18","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/ibd.20867","volume":"15","author":"D Turner","year":"2009","unstructured":"Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15:1218\u201323.","journal-title":"Inflamm Bowel Dis"},{"key":"1856_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. 2004;60:505\u201312.","journal-title":"Gastrointest Endosc"},{"key":"1856_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2036.2007.03556.x","volume":"27","author":"IM Gralnek","year":"2008","unstructured":"Gralnek IM, Defranchis R, Seidman E, et al. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther. 2008;27:146\u201354.","journal-title":"Aliment Pharmacol Ther"},{"key":"1856_CR21","first-page":"330","volume":"47","author":"J Cotter","year":"2015","unstructured":"Cotter J, de Dias Castro F, Magalhaes J, et al. Validation of the Lewis score for the evaluation of small-bowel Crohn\u2019s disease activity. Endoscopy. 2015;47:330\u20135.","journal-title":"Endoscopy"},{"key":"1856_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ibd.21649","volume":"18","author":"D Turner","year":"2012","unstructured":"Turner D, Griffiths AM, Walters TD, et al. Mathematical weighting of the pediatric Crohn\u2019s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012;18:55\u201362.","journal-title":"Inflamm Bowel Dis"},{"key":"1856_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1856_CR24","doi-asserted-by":"publisher","first-page":"e17080","DOI":"10.1097\/MD.0000000000017080","volume":"98","author":"DG Ryu","year":"2019","unstructured":"Ryu DG, Kim HW, Park SB, et al. Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis. Medicine (Baltimore). 2019;98:e17080.","journal-title":"Medicine (Baltimore)"},{"key":"1856_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.dld.2008.01.017","volume":"40","author":"RB Canani","year":"2008","unstructured":"Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547\u201353.","journal-title":"Dig Liver Dis"},{"key":"1856_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5009\/gnl17013","volume":"12","author":"S Hiraoka","year":"2018","unstructured":"Hiraoka S, Inokuchi T, Nakarai A, et al. Fecal immunochemical test and fecal calprotectin results show different profiles in disease monitoring for ulcerative colitis. Gut Liver. 2018;12:142\u20138.","journal-title":"Gut Liver"},{"key":"1856_CR27","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/jgh.14121","volume":"33","author":"C Dai","year":"2018","unstructured":"Dai C, Jiang M, Sun MJ, et al. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2018;33:990\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1856_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.cgh.2019.07.054","volume":"18","author":"M Naganuma","year":"2020","unstructured":"Naganuma M, Kobayashi T, Nasuno M, et al. Significance of conducting 2 types of fecal tests in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18:1102-1111 e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1856_CR29","doi-asserted-by":"publisher","first-page":"10617","DOI":"10.3748\/wjg.v22.i48.10617","volume":"22","author":"DG Ryu","year":"2016","unstructured":"Ryu DG, Kim HW, Park SB, et al. Assessment of disease activity by fecal immunochemical test in ulcerative colitis. World J Gastroenterol. 2016;22:10617\u201324.","journal-title":"World J Gastroenterol"},{"key":"1856_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161","author":"PF van Rheenen","year":"2020","unstructured":"van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa161.","journal-title":"J Crohns Colitis"},{"key":"1856_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ajg.2009.545","volume":"105","author":"AM Schoepfer","year":"2010","unstructured":"Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn\u2019s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162\u20139.","journal-title":"Am J Gastroenterol"},{"key":"1856_CR32","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1365-2036.2008.03835.x","volume":"28","author":"T Sipponen","year":"2008","unstructured":"Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn\u2019s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1856_CR33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","volume":"6","author":"J Jones","year":"2008","unstructured":"Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2008;6:1218\u201324.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1856_CR34","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.cgh.2018.01.024","volume":"16","author":"I Weinstein-Nakar","year":"2018","unstructured":"Weinstein-Nakar I, Focht G, Church P, et al. associations among mucosal and transmural healing and fecal level of calprotectin in children with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2018;16:1089-1097 e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1856_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cgh.2016.08.015","volume":"15","author":"T Arai","year":"2017","unstructured":"Arai T, Takeuchi K, Miyamura M, et al. Level of fecal calprotectin correlates with severity of small bowel Crohn\u2019s disease, measured by balloon-assisted enteroscopy and computed tomography enterography. Clin Gastroenterol Hepatol. 2017;15:56\u201362.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01856-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-022-01856-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01856-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T17:17:16Z","timestamp":1650388636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-022-01856-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1007\/s00535-022-01856-w","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"10 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroshi Nakase has received support from AbbVie GK., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co.,Ltd., Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co.,Ltd., Pfizer Inc, Celgene Corporation., EA Pharma Co.,Ltd., Zeria Pharmaceutical CO.,Ltd., Mochida Pharmaceutical Co.,Ltd., Nippon Kayaku Co.,Ltd., Daiichi Sankyo Company, Limited., JIMRO Co.,Ltd., as well as grants for commissioned\/joint research from Hoya Group Pentax Medical, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc, AbbVie GK., Mochida Pharmaceutical Co.,Ltd. Katsuhiro Arai received honoraria for consulting and lecture from EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and a research grant from AstraZeneca K.K. Toshiaki Shimizu is an endowed chair of Taiko Pharmaceutical and has received a research grant from the Food Science Institute Foundation and a scholarship grant from JCR Pharmaceuticals Co., Ltd. Other authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}